SCHEMBL4893063

SCHEMBL4893063

CC(C)(C)[Si](C)(C)Oc1cccc2c1OCC(=O)N2

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMYD3 Q9H7B4 1/20 0.38
PKM P14618 2/20 0.37
MAPT P10636 1/20 0.36
PRMT5 O14744 1/20 0.36
WDR77 Q9BQA1 1/20 0.36
PDE3B Q13370 1/20 0.36
PDE3A Q14432 1/20 0.36
MMP12 P39900 1/20 0.35
BRD4 O60885 1/20 0.35
CREBBP Q92793 1/20 0.35
HTR1A P08908 3/20 0.35
DRD2 P14416 1/20 0.35
HTR1D P28221 1/20 0.35
HTR1B P28222 1/20 0.35
SLC6A4 P31645 1/20 0.35
KCNH2 Q12809 1/20 0.35
ADRB2 P07550 1/20 0.34
ADRB1 P08588 1/20 0.34
OPRK1 P41145 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20597692 0.84 HTR1A (0.36) SMYD3PKMMAPTPRMT5WDR77
SCHEMBL2172798 0.80 PKM (0.44) SMYD3PKMMAPTMMP12BRD4
SCHEMBL430401 0.77 ADRB2 (0.53) HTR1AADRB2ADRB1OPRK1
SCHEMBL7737143 0.75 NR3C2 (0.46) SMYD3MAPTPRMT5WDR77MMP12
SCHEMBL4895504 0.75 EGFR (0.34) MAPTHTR1ADRD2
SCHEMBL426854 0.74 HTR1A (0.46) SMYD3HTR1ADRD2HTR1DHTR1B
SCHEMBL13145715 0.74 SMYD3 (0.42) SMYD3MMP12BRD4CREBBPHTR1A
SCHEMBL28133854 0.73 PRMT5 (0.42) SMYD3PKMMAPTPRMT5WDR77
SCHEMBL1851941 0.71 CREBBP (0.58) SMYD3PKMMMP12BRD4CREBBP
SCHEMBL29736794 0.71 SMYD3 (0.45) SMYD3PDE3BPDE3AMMP12BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds JAPAN TOBACCO INC. (JP) 2008-12-11 US disclosed
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds JAPAN TOBACCO INC. (JP) 2008-03-13 US disclosed
EP-1820515-A1 NITROGEN-CONTAINING FUSED RING COMPOUND AND USE THEREOF Japan Tobacco, Inc. (JP) 2007-08-22 EP disclosed
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof JAPAN TOBACCO INC. (JP) 2007-01-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080305169-A1 Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds NOD1, NLRP3, SLC10A1 SMYD3 3762/4885PKM 3629/4885MAPT 962/4885
US-20070010670-A1 Nitrogen-containing fused ring compounds and use thereof NUDT1, NOD1, SLC28A1 SMYD3 1040/4885PKM 4593/4885MAPT 552/4885
US-20080064871-A1 Production Method of Nitrogen-Containing Fused Ring Compounds NOD1, XDH, URB2 SMYD3 697/4885PKM 3931/4885MAPT 1019/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.